Short-term effects of empagliflozin on preventing contrast induced acute kidney injury in patients undergoing percutaneous coronary intervention, a randomised trial
Abstract Contrast-induced acute kidney injury (CI-AKI) is a prevalent cause of hospital-acquired renal impairment in patients undergoing intervention. Limited clinical trials explore SGLT2 inhibitors’ effects on CI-AKI. This study aimed to assess the short-term effect of empagliflozin- an SGLT2 inhi...
Saved in:
Main Authors: | Zeinab Sadat Hosseini, Mohammad Javad Jamili, Behzad Ensan, Ghazaleh Donyadideh, Bahram Shahri, Hamid Eshraghi, Susan Darroudi, Mohsen Moohebati |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-01-01
|
Series: | Scientific Reports |
Subjects: | |
Online Access: | https://doi.org/10.1038/s41598-024-82991-7 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical utility of combined contrast-enhanced ultrasound and intracavitary contrast-enhanced ultrasound in the percutaneous treatment of pyogenic liver abscess
by: Giampiero Francica
Published: (2024-09-01) -
Elevation of preoperative cystatin C as an early predictor of contrast-induced nephropathy in patients receiving percutaneous coronary intervention
by: Guoqiang Gu, et al.
Published: (2022-08-01) -
The Agatston score is a predictor of contrast-induced nephropathy in patients with stable coronary artery disease after percutaneous coronary intervention
by: Fatih Sivri, et al.
Published: (2024-11-01) -
Empagliflozin Alleviates Hepatic Steatosis by Activating the AMPK-TET2-Autophagy Pathway in vivo and in vitro
by: Ting Li, et al.
Published: (2021-01-01) -
Corrigendum: Empagliflozin alleviates hepatic steatosis by activating the AMPK-TET2-autophagy pathway in vivo and in vitro
by: Ting Li, et al.
Published: (2025-01-01)